Table 5 Baseline predictive factors of CS less than 7.5 mg/day analyzed by multivariate analysis
Variables | Univariate logistic regression | Multiple logistic regression | ||||
|---|---|---|---|---|---|---|
Wald | P | OR (95%CI) | Wald | P | OR (95%CI) | |
Male, n (%) | 0.9232 | 0.3365 | 0.53 (0.15–1.92) | |||
Age (years) | 5.1680 | 0.0230 | 1.07 (1.01–1.14) | 2.32 | 0.1135 | 1.06 (0.98–1.13) |
Disease duration (entero-BD, months) | 0.0186 | 0.8914 | 1.00 (0.99–1.01) | |||
Multiple ulceration, n (%) | 3.6556 | 0.1559 | 0.26 (0.06–1.03) | |||
History of relapse, n (%) | 0.3876 | 0.5336 | 0.53 (0.43–5.05) | |||
History of perforation, n (%) | 0 | 1.0000 | 1.00 (0.18–5.63) | |||
History of surgery, n (%) | 0.1704 | 0.6797 | 0.71 (0.14–3.64) | |||
Concomitant CS dose (mg/day) | 1.0678 | 0.3014 | 0.98 (0.95–1.02) | |||
Concomitant colchicine use, n (%) | 2.4121 | 0.1139 | 2.75 (0.767–9.86) | |||
Concomitant drugs use, n (%) (MTX, MS/SSZ, AZ) | 1.2318 | 0.2556 | 2.40 (0.51–11.3) | |||
Concomitant MTX use, n (%) | 11.811 | 0.0006 | 15.0 (3.20–70.4) | 2.32 | 0.5228 | 2.38 (0.16–34.2) |
TNF-i use, n (%) | 15.033 | < 0.0001 | 25.5 (4.96–131.1) | 3.11 | 0.0778 | 10.8 (0.77–153.0) |
DAIBD | 2.3752 | 0.1233 | 0.98 (0.97–1.00) | |||